Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Renal Insufficiency, Chronic 1Hematologic Neoplasms 1

Interventions

fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 2Standard of Care 2Immune Checkpoint Inhibitors 2Bevacizumab 2venetoclax 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1tipiracil 1spartalizumab 1sotorasib 1selpercatinib 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1montelukast 1malic acid 1icotinib 1gallium maltolate 1encorafenib 1eliglustat 1durvalumab 1daratumumab 1cannabigerol 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × Stem Cell Transplantation × Clear all
NCT07358195 2026-01-22

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Massachusetts General Hospital

Phase EARLY_PHASE1 Not yet recruiting
3 enrolled
Other hematologic neoplasm

Hematologic Neoplasms, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡